NICE Passes Giotrif Despite No Clinical Superiority
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has recommended Boehringer Ingelheim's Giotrif (afatinib), despite finding no clinical superiority for the drug over its rivals and saying its cost-effectiveness is difficult to determine.